Yahoo · Oct 21, 2026
Alcon's Neurotech Acquisition Offers Significant Growth Potential, Needham Says
Alcon's (ALC) acquisition of Neurotech Pharmaceuticals could become a significant revenue growth dri
AL
NYSE · ALC
Alcon Inc.
Healthcare · Medical - Instruments & Supplies
$71.45
Up+$0.32 (+0.45%)
Updated Oct 31, 2026, 5:01 PM
SID Score
6.1/10
Composite research score
Smart Money
48/100
Neutral
- Market cap
- 42.99B
- P/E ratio
- 43.53
- Dividend yield
- 0.47%
- 52-week range
- $61.84 – $87.64
- Volume
- 1.61M
- Avg. volume
- 1.54M
Price performance · ALC
ALC price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ALC closed at $71.45 after 21 trading sessions, up 12.06% for the selected period.
- Last close
- $71.45
- Period change
- +12.06%
- Period low
- $63.00
- Period high
- $71.45
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $72.34 | $72.715 | $71.27 | $71.45 | 1.61M |
| Oct 29, 2026 | $70.44 | $71.35 | $70.39 | $71.13 | 1.26M |
| Oct 28, 2026 | $68.875 | $70.08 | $68.82 | $69.83 | 1.09M |
| Oct 27, 2026 | $69.58 | $70.02 | $69.30 | $69.42 | 1.2M |
| Oct 26, 2026 | $70.08 | $70.45 | $69.70 | $69.99 | 1.46M |
| Oct 23, 2026 | $70.16 | $70.46 | $69.54 | $70.17 | 2.59M |
| Oct 22, 2026 | $68.02 | $70.68 | $67.96 | $70.63 | 2.21M |
| Oct 21, 2026 | $67.555 | $68.09 | $67.09 | $67.43 | 1.1M |
| Oct 20, 2026 | $67.39 | $67.91 | $67.105 | $67.83 | 978.65K |
| Oct 19, 2026 | $65.50 | $66.16 | $65.44 | $66.13 | 1.1M |
| Oct 16, 2026 | $66.95 | $67.02 | $66.04 | $66.18 | 1.45M |
| Oct 15, 2026 | $65.44 | $66.79 | $65.02 | $66.58 | 2.4M |
| Oct 14, 2026 | $63.93 | $64.13 | $63.17 | $63.87 | 1.72M |
| Oct 13, 2026 | $63.91 | $64.19 | $62.10 | $63.00 | 2.5M |
| Oct 12, 2026 | $64.28 | $64.52 | $63.83 | $64.35 | 1.84M |
| Oct 9, 2026 | $63.87 | $64.195 | $63.53 | $64.11 | 1.35M |
| Oct 8, 2026 | $62.49 | $63.295 | $62.43 | $63.13 | 1.19M |
| Oct 7, 2026 | $63.36 | $63.685 | $62.94 | $63.00 | 1.54M |
| Oct 6, 2026 | $64.16 | $64.19 | $62.99 | $63.19 | 2.39M |
| Oct 5, 2026 | $63.65 | $64.35 | $63.55 | $64.33 | 1.38M |
| Oct 2, 2026 | $64.39 | $64.42 | $63.50 | $63.76 | 1.27M |
Latest ALC news
The latest Smart Investors Daily articles mentioning ALC.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ALC research
Overview
Company profile and research snapshot.
Company profile
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $92.35
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 21, 2026 | BERENBERG | Buy | — |
| Aug 31, 2026 | BNP PARIBAS | Neutral | — |
| Aug 14, 2026 | EQUITA SIM | Buy | — |
| Aug 11, 2026 | NEEDHAM & COMPANY INC. | Buy | — |
| Jul 20, 2026 | DAY BY DAY | Sell | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 21, 2026
Needham Reiterates Buy on Alcon, Maintains $98 Price Target
Needham analyst David Saxon reiterates Alcon (NYSE:ALC) with a Buy and maintains $98 price target.
Yahoo · Oct 20, 2026
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
GENEVA, October 20, 2026--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2
Benzinga · Oct 20, 2026
Alcon Acquires Neurotech Pharmaceuticals For $550M
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company focused on developing innovative cell
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
